{
    "pmcid": "10892724",
    "qa_pairs": {
        "What is the primary target for neutralizing antibodies on the SARS-CoV-2 spike protein according to the study?": [
            "The receptor binding domain (RBD)",
            "The S2 subunit",
            "The N-terminal domain (NTD)",
            "The glycan shield"
        ],
        "What potential advantage do nanobodies have over conventional antibodies as mentioned in the study?": [
            "They have a lower risk of inducing anti-drug antibodies (ADAs)",
            "They have a higher molecular weight",
            "They require more complex production processes",
            "They are less stable"
        ],
        "What was the observed effect of intranasal administration of nanobodies in transgenic mice?": [
            "Reduced viral loads in the nasal turbinates and brain",
            "Increased viral replication in the lungs",
            "No change in viral load in any tissues",
            "Increased viral load in the brain"
        ],
        "Which domain of the spike protein is less commonly targeted by nanobodies but still plays a role in viral infectivity and immune evasion?": [
            "The N-terminal domain (NTD)",
            "The receptor binding domain (RBD)",
            "The S2 subunit",
            "The furin cleavage site"
        ],
        "Which nanobody was capable of neutralizing all tested SARS-CoV-2 variants in its monomeric form?": [
            "Nb-45",
            "Nb-23",
            "Nb-67",
            "Nb-89"
        ]
    }
}